US FDA issues biosimilar CRL to ‘disappointed’ but determined Sandoz
The US FDA has rejected Sandoz’s proposed biosimilar version of Biogen and Roche’s Rituxan (rituximab).
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs